PRE‐CLINICAL EVIDENCE FOR THE USE OF PHOSPHODIESTERASE‐5 INHIBITORS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS